Logo image
Heterogeneity of Nephrotoxic Risk Across Medication Classes and Combinations in Hospitalized Adults
Journal article   Peer reviewed

Heterogeneity of Nephrotoxic Risk Across Medication Classes and Combinations in Hospitalized Adults

Yaohua Wang, Casey G Hardin, Mary Vaughan-Sarrazin, Melissa Swee, Masaaki Yamada, Michael Tabet, Jason Misurac, Brian C Lund, W Nick Street, Diana I Jalal, …
Kidney360
09/01/2026
DOI: 10.34067/KID.0000001346
PMID: 42678799

View Online

Abstract

Drug-associated acute kidney injury (DA-AKI) is common among hospitalized patients receiving multiple medications. Nephrotoxicity is often treated as a binary categorization, but AKI risk likely varies across medication classes and combinations. We sought to characterize class-specific AKI associations and evaluate whether medication-class interactions associate with DA-AKI prediction. This retrospective observational study included adults admitted to the University of Iowa from 2014-2023 who met high nephrotoxin exposure criteria, defined as receipt of ≥3 concurrent potentially nephrotoxic medications. The primary outcome was stage 2/3 AKI within 7 days of initial high-nephrotoxin exposure. Models adjusted for demographics, comorbidities, admission diagnosis, laboratory values, and vital signs at index exposure. Generalized estimating equation logistic models were used to estimate medication-class associations and test 66 two-way class interactions. XGBoost models were used to explore nonlinear and higher-order exposure patterns. We evaluated 66,977 admissions with high-nephrotoxin exposure from 42,558 patients, with stage 2/3 AKI developing in 3,309 (5%). Adjusted odds ratios ranged from 0.74 (95% CI 0.64-0.87) for NSAID exposure to 1.71 (95% CI 1.55-1.88) for piperacillin-tazobactam, indicating substantial heterogeneity in class-specific associations with AKI. Among 66 medication-class pairs tested, 9 (14%) remained statistically significant after multiple-comparison adjustment. Inclusion of medication class and pairwise terms was associated with increased GEE discrimination from ROC-AUC 0.73 to 0.76 and PR-AUC 0.16 to 0.17. XGBoost achieved ROC-AUC 0.78 and PR-AUC 0.20, suggesting additional nonlinear or higher-order exposure patterns. Among hospitalized adults with high nephrotoxin exposure, medication class composition and pairwise exposure patterns were associated with subsequent stage 2/3 AKI. These findings support evaluation of weighted nephrotoxin surveillance frameworks incorporating medication class, combinations, and clinical context.

Details

Metrics

4 Record Views
Logo image